Knowledge Ecology International

SEARO RC70: India calls on WHO to take the lead in negotiations of the R&D treaty (General Programme of Work debate)

Posted on September 24, 2017 by Thiru

As noted in an earlier piece, on 25 August 2017 the WHO published a draft concept note to provide a road map to “underpin WHO’s General Programme of of Work from 2019-2023… and serve as the strategic basis for resource mobilization” for the Organization (WHO draft concept note on strategic priorities for 2019-2023 charts a new vision for the organization, 29 August 2017, KEI). Continue Reading →

Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria unanimously endorses delinkage

Posted on September 17, 2017 by James Love

On Thursday, the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria unanimously endorsed a report that included very powerful recommendations on delinkage. This is a link to the report that was approved.

This from the report:

Adoption of some form of a delinkage model as a pull incentive.
Continue Reading →

KEI asks HHS to use Bayh-Dole rights in Zinbryta patent (drug for multiple sclerosis)

Posted on September 15, 2017 by KEI Staff

Attached is a letter sent on September 14, 2017 to Andrew Bremberg, an Assistant to the President and the Director of the Domestic Policy Council at the White House, and Keagan Lenihan, a Senior Adviser to HHS Secretary Tom Price, regarding Zinbrytra (INN: daclizumab), a drug to approved by the FDA to treat multiple sclerosis. (PDF version here)

Continue Reading →

SEARO RC70: Statement of Knowledge Ecology International on Access to Medicines

Posted on September 9, 2017 by Thiru

Knowledge Ecology International (KEI) delivered the following statement during discussions at the WHO South East Asia Region (SEARO) Regional Committee on Access to Medicines on 9 September 2017 in the Maldives.

(Photo taken by Cristina Bajar)

Intervention of Knowledge Ecology International

Seventieth Session of the Regional Committee – SEARO: 8.3 Access to medicines – SEA/RC70/9
Saturday, 9 September 2017

Continue Reading →

Access to Medicine, Transparency SEARO, World Health Organization

2017: Nanobernetics proposed exclusive license for NIH patents on Apparatus for Microarray Binding Sensors

Posted on September 6, 2017 by Kim Treanor

(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) The attached file (copy here) is the KEI questions and initial comments on the Prospective Grant of an Exclusive Patent License: Apparatus for Microarray Binding Sensors Having… Continue Reading →

2017: Kymriah, the Novartis $475,000 CAR T treatment, received 50 percent Orphan Drug tax credit on trials

Posted on August 31, 2017 by James Love

Missing in the reporting on the Novartis price for Kymriah, its new $475,000 CAR T treatment, is that Novartis received an Orphan Drug designation in February 3, 2015, and sequently received a tax credit subsidy from the United States equal to 50 percent of the cost of qualifying clinical trials.

From the FDA database on Orphan Designations:
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=463114

Continue Reading →

US Federal rights in patents on Probuphine, to treat opioid addiction

Posted on August 30, 2017 by Kim Treanor

Probuphine is an expensive medication used to treat opioid dependence by providing maintenance treatment and lessening withdrawal symptoms. The U.S. federal government also has considerable leverage over the pricing of this product, because of the federal funding of the the research that lead to the sole Orange Book patent on the product, and phase 3 trials that were used the register the product.

Continue Reading →

WHO draft concept note on strategic priorities for 2019-2023 charts a new vision for the organization

Posted on August 29, 2017 by Thiru

On 25 August 2017, the World Health Organization (WHO) published a draft concept note to provide a strategic framework to underpin WHO’s General Programme of of Work from 2019-2023. Continue Reading →

KEI statement regarding Gilead’s Acquisition of Kite Pharma

Posted on August 28, 2017 by James Love

KEI statement regarding Gilead’s Acquisition of Kite Pharma.

“Congress should require the NIH to enforce the Bayh-Dole obligation to make the Kite Pharma Chimeric Antigen Receptors Technologies (CAR T) treatments available to the public on reasonable terms.

KEI notes that Kite reported spending $317 million in R&D from 2012 to June 30, 2017, and is selling the company for $11.9 billion.

Continue Reading →

Workshop: Patents, the Public Interest and Two New Medical Technologies: CRISPR and CAR T

Posted on August 25, 2017 by Kim Treanor

Workshop: Patents, the Public Interest and Two New Medical Technologies: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), Chimeric Antigen Receptors (CAR) technologies

On September 15th, 2017, Knowledge Ecology International will be hosting a workshop on: “Patents, the Public Interest and Two New Medical Technologies: CRISPR and CAR T.”

If you are unable to attend in person, a livestream of the event will be available here

Continue Reading →

Categories